EMA Authorised: Ayvakyt (avapritinib) — Blueprint Medicines (Netherlands) B.V.

View source ↗

Summary

The European Medicines Agency authorised Ayvakyt (avapritinib) for gastrointestinal stromal tumors with conditional approval and orphan designation, with Bluepr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Ayvakyt (avapritinib)

Snippet

Status: Authorised. Therapeutic area: Gastrointestinal Stromal Tumors. MAH: Blueprint Medicines (Netherlands) B.V.. Decision date: 27/11/2025. Conditional approval. Orphan medicine